Evidence map›Paper›PMID 40427050›Full record

ArticleBiomedicines2025

Extended Toxicity, Genotoxicity, and Mutagenicity of Combination of pBudK-coVEGF-coANG and pBudK-coGDNF Plasmids in Preclinical Trials.

Igor V Samatoshenkov, Alexander M Aimaletdinov, Elena Y Zakirova, Egan L Kalmykov, Rustam Khodzhibaev, Yulia M Samatoshenkova, Ilnur M Ganiev, Marat S Kadyrov, Yana O Mukhamedshina

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Igor V SamatoshenkovMedizinische Hochschule Brandenburg Theodor Fontane, 14770 Brandenburg, Germany.ORCID 0000-0002-6836-7285
Alexander M AimaletdinovInstitute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia.
Elena Y ZakirovaInstitute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia.
Egan L KalmykovDepartment of Vascular and Endovascular Surgery, Brandenburg University Clinic, 14770 Brandenburg, Germany.
Rustam KhodzhibaevDepartment of Vascular and Endovascular Surgery, Brandenburg University Clinic, 14770 Brandenburg, Germany.
Yulia M SamatoshenkovaSAHI Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, 420138 Kazan, Russia.
Ilnur M GanievInstitute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia.ORCID 0000-0002-6171-5347
Marat S KadyrovLimited Liability Company "Angiolife", 420015 Kazan, Russia.
Yana O MukhamedshinaInstitute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia.ORCID 0000-0002-9435-340X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lower limb ischemia is a debilitating condition, particularly prevalent among elderly patients and individuals ineligible for revascularization procedures. Gene therapy aimed at promoting therapeutic angiogenesis presents a promising alternative treatment strategy.

Indexed as

angiogeningenetic therapyglial-derived neurotrophic factorischemic diseaseplasmidvascular endothelial growth factor

Identifiers

PMID40427050
PMCPMC12109478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.